NASDAQ:SABS SAB Biotherapeutics (SABS) Stock Forecast, Price & News $0.95 +0.01 (+1.06%) (As of 06/6/2023 ET) Add Compare Share Share Today's Range$0.90▼$0.9550-Day Range$0.38▼$1.0952-Week Range$0.37▼$1.93Volume100,380 shsAverage Volume816,805 shsMarket Capitalization$47.87 millionP/E RatioN/ADividend YieldN/APrice Target$3.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media SAB Biotherapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside286.0% Upside$3.67 Price TargetShort InterestHealthy1.87% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.53) to ($0.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.09 out of 5 starsMedical Sector427th out of 981 stocksBiological Products, Except Diagnostic Industry63rd out of 156 stocks 3.5 Analyst's Opinion Consensus RatingSAB Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.67, SAB Biotherapeutics has a forecasted upside of 286.0% from its current price of $0.95.Amount of Analyst CoverageSAB Biotherapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.87% of the float of SAB Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverSAB Biotherapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SAB Biotherapeutics has recently increased by 28.31%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSAB Biotherapeutics does not currently pay a dividend.Dividend GrowthSAB Biotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SABS. Previous Next 2.4 News and Social Media Coverage News SentimentSAB Biotherapeutics has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.Search InterestOnly 11 people have searched for SABS on MarketBeat in the last 30 days. This is a decrease of -15% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added SAB Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -86% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SAB Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders31.90% of the stock of SAB Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 20.94% of the stock of SAB Biotherapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for SAB Biotherapeutics are expected to grow in the coming year, from ($0.53) to ($0.44) per share.Price to Book Value per Share RatioSAB Biotherapeutics has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About SAB Biotherapeutics (NASDAQ:SABS) StockSAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.Read More Receive SABS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SABS Stock News HeadlinesMay 30, 2023 | finance.yahoo.comSAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International ConventionMay 30, 2023 | americanbankingnews.comSAB Biotherapeutics, Inc. (NASDAQ:SABS) Sees Large Growth in Short InterestJune 6, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!May 23, 2023 | americanbankingnews.comFY2023 EPS Estimates for SAB Biotherapeutics, Inc. Raised by Chardan Capital (NASDAQ:SABS)May 19, 2023 | finance.yahoo.comSAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy InnovationsMay 19, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for SAB Biotherapeutics, Inc. (NASDAQ:SABS) Boosted by AnalystMay 16, 2023 | msn.comSAB Biotherapeutics: Q1 Earnings InsightsMay 16, 2023 | finanznachrichten.deSAB Biotherapeutics, Inc.: SAB Biotherapeutics Provides Company Update for Q1 2023 Financial ResultsJune 6, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Software" to Revolutionize WarfareThis breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>May 16, 2023 | finance.yahoo.comSAB Biotherapeutics Provides Company Update for Q1 2023 Financial ResultsMay 12, 2023 | finance.yahoo.comSAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal AntibodiesMay 11, 2023 | barrons.comSAB Biotherapeutics Inc.May 9, 2023 | marketwatch.comSAB Biotherapeutics Announces Progress on U.S. FDA's Phased Review of Company's Groundbreaking DiversitAb(TM) PlatformMay 4, 2023 | msn.comEXCLUSIVE: SAB Biotherapeutics' Influenza Immunotherapy Shows Safety, Efficacy In Early-Stage TrialsMay 3, 2023 | finance.yahoo.comSAB Biotherapeutics to Present at Sidoti Virtual Investor Conference, May 10-11April 29, 2023 | marketwatch.com8-K: SAB Biotherapeutics, Inc.April 26, 2023 | finance.yahoo.comSAB Biotherapeutics Sees Positive Results from COVID Drug SAB-185April 26, 2023 | msn.comEXCLUSIVE: SAB Biotherapeutics Releases Topline Data From Discontinued COVID Antibody TrialApril 26, 2023 | finance.yahoo.comSAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe ComplicationsApril 22, 2023 | americanbankingnews.comHC Wainwright Analysts Cut Earnings Estimates for SAB Biotherapeutics, Inc. (NASDAQ:SABS)April 21, 2023 | americanbankingnews.comSAB Biotherapeutics, Inc. Forecasted to Post FY2023 Earnings of ($0.52) Per Share (NASDAQ:SABS)April 19, 2023 | morningstar.comSAB Biotherapeutics Shares Soar on FDA's Breakthrough DesignationApril 18, 2023 | msn.comSAB Biotherapeutics Blasts Up on Flu TreatmentsApril 18, 2023 | benzinga.comShort Volatility Alert: Sab BiotherapeuticsApril 18, 2023 | benzinga.comEXCLUSIVE: SAB Biotherapeutics Secures FDA Breakthrough Therapy Tag For Its Influenza ImmunotherapyApril 18, 2023 | finance.yahoo.comSAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza ImmunotherapyApril 13, 2023 | msn.comWhy Is SAB Therapeutics Stock Trading Higher Today?See More Headlines SABS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SABS Company Calendar Last Earnings5/16/2023Today6/06/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SABS CUSIPN/A CIK1833214 Webwww.bigcypressaccorp.com Phone605-679-6980FaxN/AEmployees139Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.67 High Stock Price Forecast$4.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+286.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,740,000.00 Net Margins-213.54% Pretax Margin-214.06% Return on Equity-87.92% Return on Assets-52.78% Debt Debt-to-Equity Ratio0.17 Current Ratio1.10 Quick Ratio1.10 Sales & Book Value Annual Sales$23.90 million Price / Sales2.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book1.32Miscellaneous Outstanding Shares50,400,000Free Float34,321,000Market Cap$47.88 million OptionableNot Optionable Beta1.41 Key ExecutivesMr. Samuel J. Reich (Age 48)Exec. Chairman Comp: $212.58kDr. Eddie Joe Sullivan Ph.D. (Age 57)Co-Founder, Pres, CEO & Director Comp: $526.82kMs. Christine E. Hamilton M.B.A. (Age 67)Co-Founder & Independent Director Comp: $25kDr. Edward D. Hamilton D.V.M.Co-Founder & Board ObserverMr. Russell P. Beyer C.M.A. (Age 68)M.B.A., Exec. VP & CFO Dr. Christoph Bausch M.B.A. (Age 52)Ph.D., Exec. VP & COO Dr. Carlos N. Carillo Ph.D.Sr. VP of Regulatory AffairsDr. Alexandra Kropotova M.B.A. (Age 51)M.D., Exec. VP & Chief Medical Officer More ExecutivesKey CompetitorsAcorda TherapeuticsNASDAQ:ACORCurisNASDAQ:CRISCortexymeNASDAQ:CRTXTaysha Gene TherapiesNASDAQ:TSHAGreenLight BiosciencesNASDAQ:GRNAView All CompetitorsInsiders & InstitutionsFirst Manhattan CO. LLC.Bought 277,777 shares on 5/16/2023Ownership: 0.551%Christine E HamiltonBought 10,000 shares on 9/13/2022Total: $7,300.00 ($0.73/share)View All Insider TransactionsView All Institutional Transactions SABS Stock - Frequently Asked Questions Should I buy or sell SAB Biotherapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SAB Biotherapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SABS shares. View SABS analyst ratings or view top-rated stocks. What is SAB Biotherapeutics' stock price forecast for 2023? 2 Wall Street research analysts have issued twelve-month target prices for SAB Biotherapeutics' shares. Their SABS share price forecasts range from $3.00 to $4.00. On average, they expect the company's stock price to reach $3.67 in the next year. This suggests a possible upside of 286.0% from the stock's current price. View analysts price targets for SABS or view top-rated stocks among Wall Street analysts. How have SABS shares performed in 2023? SAB Biotherapeutics' stock was trading at $0.5899 on January 1st, 2023. Since then, SABS shares have increased by 61.0% and is now trading at $0.95. View the best growth stocks for 2023 here. Are investors shorting SAB Biotherapeutics? SAB Biotherapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 665,400 shares, an increase of 28.3% from the April 30th total of 518,600 shares. Based on an average daily trading volume, of 1,310,000 shares, the short-interest ratio is presently 0.5 days. Currently, 1.9% of the shares of the company are short sold. View SAB Biotherapeutics' Short Interest. When is SAB Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our SABS earnings forecast. How were SAB Biotherapeutics' earnings last quarter? SAB Biotherapeutics, Inc. (NASDAQ:SABS) posted its earnings results on Tuesday, May, 16th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.07. The business earned $0.58 million during the quarter, compared to the consensus estimate of $5.56 million. SAB Biotherapeutics had a negative trailing twelve-month return on equity of 87.92% and a negative net margin of 213.54%. What is SAB Biotherapeutics' stock symbol? SAB Biotherapeutics trades on the NASDAQ under the ticker symbol "SABS." Who are SAB Biotherapeutics' major shareholders? SAB Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include First Manhattan CO. LLC. (0.55%). View institutional ownership trends. How do I buy shares of SAB Biotherapeutics? Shares of SABS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is SAB Biotherapeutics' stock price today? One share of SABS stock can currently be purchased for approximately $0.95. How much money does SAB Biotherapeutics make? SAB Biotherapeutics (NASDAQ:SABS) has a market capitalization of $47.88 million and generates $23.90 million in revenue each year. How many employees does SAB Biotherapeutics have? The company employs 139 workers across the globe. How can I contact SAB Biotherapeutics? SAB Biotherapeutics' mailing address is 300 W. 41ST STREET SUITE 202, MIAMI BEACH FL, 33140. The official website for the company is www.bigcypressaccorp.com. The company can be reached via phone at 605-679-6980 or via email at ir@bigcypressaccorp.com. This page (NASDAQ:SABS) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.